Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Indonesian Journal of Obstetrics & Gynecology Science
A.W., Gatot Nyarumenteng
Unknown Affiliation
Health Professions Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
HALP and SII: Innovative Biomarkers for Diagnosing Ovarian Cancer in Both Epithelial and Non-Epithelial Subtypes Ridwan, Steven; Mantilidewi, Kemala Isnainiasih; A.W., Gatot Nyarumenteng; Kurniadi, Andi; Suardi, Dodi; Salima, Siti; Rauf, Syahrul; Hidayat, Yudi Mulyana
Indonesian Journal of Obstetrics & Gynecology Science Volume 8 Nomor 2 July 2025
Publisher : Dep/SMF Obstetri & Ginekologi Fakultas Kedokteran Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/obgynia.v8i2.882

Abstract

Objective: To evaluate the diagnostic utility of PHAL (Platelet, Hemoglobin, Albumin, and Lymphocyte), SII (Systemic Immune Inflammation Index), and SIRI (Systemic Inflammatory Response Index) for both epithelial and non-epithelial ovarian cancer.Methods: A cross-sectional study of 156 patients with ovarian masses was conducted using preoperative laboratory data to calculate PHAL, SII, and SIRI scores. Histopathology confirmed diagnoses. Population I included all ovarian cancer types and benign tumors, while Population II included only non-epithelial ovarian cancer and benign tumors. Statistical analysis using SPSS 25.0, involved ROC curve and validity testing to assess diagnostic performance.Result: SII showed the best performance in the overall population (AUC 0.738; sensitivity 71.25%; specificity 72.37%; accuracy 71.79%; LR+ 2.58; LR– 0.40). In the subgroup of non-epithelial ovarian cancer versus benign tumors, PHAL had the highest diagnostic accuracy (AUC 0.819; sensitivity 81.81%; specificity 73.68%; accuracy 75.51%; LR+ 3.11; LR– 0.25).Conclusion: PHAL and SII are effective, accessible, and low-cost biomarkers that can support ovarian cancer diagnosis through routine blood tests.PHAL dan SII: Biomarker Inovatif untuk Diagnosis Kanker Ovarium Subtipe Epitel dan Non-Epitel Abstrak Tujuan: Penelitian ini bertujuan untuk mengevaluasi nilai diagnostik dari PHAL (Platelet, Haemoglobin, Albumin, dan Limfosit), SII (Systemic Immune Inflammation Index), dan SIRI (Systemic Inflammatory Response Index) pada kanker ovarium epitelial dan non-epitelial. Metode: Penelitian dengan metode potong lintang ini melibatkan 156 pasien dengan massa ovarium. Data laboratorium pra-operatif digunakan untuk menghitung skor PHAL, SII, dan SIRI. Diagnosis ditegakkan melalui pemeriksaan histopatologi. Populasi I mencakup semua jenis kanker ovarium dan tumor jinak, sedangkan Populasi II hanya mencakup kanker ovarium non-epitelial dan tumor jinak. Analisis statistik dilakukan menggunakan SPSS 25.0, termasuk analisis kurva ROC dan uji validitas untuk menilai kinerja diagnostik. Hasil: Hasil penelitian menyimpulkan bahwa SII memiliki performa terbaik pada seluruh populasi (AUC 0,738; sensitivitas 71,25%; spesifisitas 72,37%; akurasi 71,79%; LR+ 2,58; LR– 0,40). Pada subkelompok kanker ovarium non-epitelial dibandingkan dengan tumor jinak, PHAL menunjukkan akurasi diagnostik tertinggi (AUC 0,819; sensitivitas 81,81%; spesifisitas 73,68%; akurasi 75,51%; LR+ 3,11; LR– 0,25). Kesimpulan: PHAL dan SII merupakan biomarker yang efektif, mudah diakses, dan berbiaya rendah yang dapat mendukung diagnosis kanker ovarium melalui pemeriksaan darah rutin. Kata kunci: Kanker ovarium, Skor PHAL (Platelet-Hemoglobin-Albumin-Limfosit), Systemic Immune-Inflammation Index, Systemic Inflammatory Response Index
Comparison of Chondroitin Sulfate-E Expression in Benign and Malignant Epithelial Type Ovarian Tumors Mantilidewi, Kemala Isnainiasih; A.W., Gatot Nyarumenteng; Kurniadi, Andi; Suardi, Dodi; Harsono, Ali Budi; Salima, Siti; A, Aditiyono; Hapsari, Kartika; Yantisetiasti, Anglita
Indonesian Journal of Obstetrics & Gynecology Science Volume 8 Nomor 2 July 2025
Publisher : Dep/SMF Obstetri & Ginekologi Fakultas Kedokteran Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/obgynia.v8i2.861

Abstract

Objective: Ovarian cancer is the fifth leading cause of cancer-related death in women, due to late diagnosis and limited screening methods. Chondroitin Sulfate-E (CS-E) has shown potential as biomarkers. This study aims to evaluate CS-E expression in epithelial-type benign and malignant ovarian tumors and its potential as a biomarker using QuPath software.Methods: This observational analytic study used a cross-sectional design. Samples were selected based on histopathology of patients with epithelial-type benign and malignant ovarian tumors from surgeries in 2023. Immunohistochemistry using the GD3G7 antibody was performed to detect CS-E expression in tumor tissues preserved in paraffin blocks at Dr. Hasan Sadikin General Hospital Bandung. Expression was quantified using QuPath software. Statistical analysis used the Mann-Whitney and t-test. Result: No significant difference in CS-E expression was found between malignant and benign tumors (p = 0.492). Demographic factors (age, BMI, menopausal status, and parity) showed no significant differences between groups. Conclusion: CS-E expression has not yet demonstrated potential as a biomarker to distinguish between benign and malignant ovarian tumors.Perbandingan Ekspresi Chondroitin Sulfate-E pada Tumor Ovarium Jinak dan Ganas Tipe Epitel Abstrak Tujuan: Kanker ovarium merupakan penyebab kematian kelima terbanyak terkait kanker pada wanita yang disebabkan oleh keterlambatan diagnosis dan keterbatasan metode skrining. Chondroitin Sulfate-E (CS-E) menunjukkan potensi sebagai biomarker. Penelitian ini bertujuan mengevaluasi ekspresi CS-E pada tumor ovarium jinak dan ganas tipe epitelial serta menilai potensinya sebagai biomarker menggunakan perangkat lunak QuPath. Metode: Penelitian analitik observasional ini menggunakan desain potong lintang. Sampel dipilih berdasarkan hasil histopatologi pasien dengan tumor ovarium jinak dan ganas tipe epitelial dari operasi tahun 2023. Pemeriksaan imunohistokimia dengan antibodi GD3G7 dilakukan untuk mendeteksi ekspresi CS-E pada jaringan tumor yang diawetkan dalam blok parafin di RSUP Dr. Hasan Sadikin Bandung. Ekspresi dianalisis secara kuantitatif menggunakan perangkat lunak QuPath. Uji statistik yang digunakan adalah Mann-Whitney dan uji t. Hasil: Tidak ditemukan perbedaan bermakna dalam ekspresi CS-E antara tumor ganas dan jinak (p = 0,492). Faktor demografis (usia, indeks massa tubuh, status menopause, dan paritas) juga tidak menunjukkan perbedaan bermakna antar kelompok.Kesimpulan: Ekspresi CS-E belum menunjukkan potensi sebagai biomarker untuk membedakan antara tumor ovarium jinak dan ganas. Kata kunci: Biomarker, GD3G7, Glikosaminoglikan, Kanker Ovarium, Kondroitin sulfat 
Co-Authors A, Aditiyono Andi Kurniadi, Andi Anglita Yantisetiasti Dodi Suardi Harsono, Ali Budi Kartika Hapsari Kemala Isnainiasih Mantilidewi Salima, Siti Steven Ridwan, Steven Syahrul Rauf Yudi Mulyana Hidayat